Show simple item record

dc.contributor.authorJones, Steve
dc.date.accessioned2020-02-05T12:46:25Z
dc.date.available2020-02-05T12:46:25Z
dc.date.issued2019-11
dc.identifier.citationAnna Santarsieri,et al; Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious. Blood 2019; 134 (Supplement_1): 1564. doi: https://doi.org/10.1182/blood-2019-125256en
dc.identifier.urihttps://orda.derbyhospitals.nhs.uk/handle/123456789/2189
dc.descriptionAvailable on publishers website.en
dc.description.abstractSince interim results from the EuroNet-PHL-C1 study1were published in 2013 showing that the gonadotoxic drug procarbazine in COPP can be safely replaced with dacarbazine (COPDac) it is increasingly common practice to modify escalated BEACOPP (eBPP) by removing oral procarbazine and replacing it with intravenous dacarbazine (250mg/m2 D2-3), hoping to reduce haematopoietic stem cell and gonadal toxicity. However, published data of 'escalated BEACOPDac (eBPDac)' regimen are very limited.en
dc.language.isoenen
dc.subjectHodgkin Diseaseen
dc.subjectProcarbazineen
dc.subjectPatient Safetyen
dc.subjecteBPDac Therapyen
dc.titleProcarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficaciousen
dc.typeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record